{"id":"NCT00637377","sponsor":"Bayer","briefTitle":"Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)","officialTitle":"A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-04","primaryCompletion":"2010-09","completion":"2011-08","firstPosted":"2008-03-18","resultsPosted":"2012-01-23","lastUpdate":"2014-12-12"},"enrollment":1240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration"],"interventions":[{"type":"DRUG","name":"Ranibizumab","otherNames":[]},{"type":"BIOLOGICAL","name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"type":"BIOLOGICAL","name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]},{"type":"BIOLOGICAL","name":"Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)","otherNames":[]}],"arms":[{"label":"Ranibizumab 0.5mg Q4","type":"ACTIVE_COMPARATOR"},{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4","type":"EXPERIMENTAL"},{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4","type":"EXPERIMENTAL"},{"label":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8","type":"EXPERIMENTAL"}],"summary":"This study is a phase III, double-masked, randomized, study of the efficacy and safety of VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately 1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.","primaryOutcome":{"measure":"Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)","timeFrame":"At week 52","effectByArm":[{"arm":"Ranibizumab 0.5mg Q4","deltaMin":94.42,"sd":null},{"arm":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4","deltaMin":95.62,"sd":null},{"arm":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4","deltaMin":96.27,"sd":null},{"arm":"Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8","deltaMin":95.56,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG000 vs OG003","p":null}]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":189,"countries":["Argentina","Australia","Austria","Belgium","Brazil","Colombia","Czechia","France","Germany","Hungary","India","Israel","Italy","Japan","Latvia","Mexico","Netherlands","Poland","Portugal","Singapore","Slovakia","South Korea","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["23084240","24084500","36932356","31826853","25439429","25107900"],"seeAlso":["http://clinicaltrials.gov/ct2/show/NCT00509795?term=NCT00509795;rank=1","http://www.clinicaltrialsregister.eu/"]},"adverseEventsSummary":{"seriousAny":{"events":65,"n":291},"commonTop":["Retinal haemorrhage","Visual acuity reduced","Macular degeneration","Hypertension","Conjunctival haemorrhage"]}}